Wilson’s disease is a rare genetic disorder characterized by excess copper stored in various body tissues, particularly in the liver, brain, and corneas of the eyes. The body needs a small amount of copper from food to be healthy, but excess copper is harmful. If Wilson’s disease is not treated it may lead to organ damage. Wilson’s disease is present in a person from birth; however, the symptoms don’t appear until the level of copper rises up the liver, the brain, or the other organs. The symptoms are related to the liver, nervous system and mental health, eyes, or other organs. Wilson’s disease develops symptoms related to the liver, such as hepatitis and inflammation of the liver. Nervous system and mental health symptoms include difficulty in speaking, stiff muscles, anxiety, and depression. Wilson’s disease is caused due to the mutation of the ATP7B gene. These gene mutations prevent the body from removing extra copper.

Market Dynamics

The increasing number of clinical trials by market players is expected to drive the growth of Colombia, Chile and Peru Wilson’s disease treatment market during the forecast period. For instance, Alexion Pharmaceuticals, Inc., a subsidiary of AstraZeneca Plc., started a clinical trial of drug: ALXN1840, indicated for the treatment of Wilson’s disease. The study started in October 2021 and is expected to end in May 2024. The study is in Phase III.

Increasing inorganic growth strategies such as partnerships of pharmaceutical companies with local distributors for the distribution of medicines in the Peru is expected to drive the growth of Colombia, Peru and Chile Wilson’s disease treatment market. For instance, according to the International Trade Administration data of 2018, the U.S is the largest exporter of healthcare goods and services to Peru at 21.7% market share. This makes U.S. manufacturers to maintain good relations with local distributors, to provide after- sales services for medical devices.

Key features of the study

• This report provides an in-depth analysis of Colombia, Chile and Peru Wilson’s disease treatment market, market size (USD Thousand), and compound annual growth rate (CAGR %) for the forecast period (2022-2030), considering 2021 as the base year.
• It elucidates potential revenue opportunities across different segments and explains an attractive investment proposition matrix for this market
• This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, regional outlook, and competitive strategies adopted by the leading players
• It profiles leading players in Colombia, Chile and Peru Wilson’s treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
• Key companies covered as a part of this study include Teva Pharmaceutical Industries Ltd., Bausch Health Companies Inc., Alexion Pharmaceutical, Inc., and SanofiA.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launch, technology up-gradation, market expansion, and marketing tactics.
• The Colombia, Chile and Peru Wilson’s treatment market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision making through various strategy matrices used in analyzing Colombia, Chile and Peru Wilson’s disease treatment

Market Segmentation

• By Drugs Insights (Revenue, USD Mn, 2020 - 2033)
  • D- Penicillamine
  • Trientine, Zinc Acetate
• By Distribution Channel Insights (Revenue, USD Mn, 2020 - 2033)
  • Hospital Pharmacies
  • Government Distribution Channels
• By Region Insights (Revenue, USD Mn, 2020 - 2033)
  • Colombia
  • Chile
  • Peru
• Key Players
  • Teva Pharmaceuticals Industries Ltd.
  • Bausch Health Companies Inc.
  • Alexion Pharmaceutical, Inc.
  • Sanofi S.A.